Cited by 1,200Dermatology and Skin DiseasesReliability and Agreement in MeasurementContact Dermatitis and Allergies

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis

Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., Evaluator Group, The Easi·2001·Experimental Dermatology

DOI 10.1034/j.1600-0625.2001.100102.x

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To test the reliability of the eczema area and severity index (EASI) scoring system by assessing inter- and intra-observer consistency. DESIGN: Training of evaluators, application, and assessment over 2 consecutive days. SETTING: An academic center. PATIENTS: Twenty adults and children with atopic dermatitis (AD); cohort 1 (10 patients > or = 8 years) and cohort 2 (10 patients < 8 years). INTERVENTIONS: None. MAIN OUTCOME MEASURE: The EASI was used by 15 dermatologist evaluators to assess atopic dermatitis in cohort 1 and cohort 2 on 2 consecutive days. Inter- and intraobserver reliability were analyzed. RESULTS: Overall intra-evaluator reliability of the EASI was in the fair-to-good range. Inter-evaluator reliability analyses indicated that the evaluators assessed the patients consistently across both study days. CONCLUSIONS: This study demonstrated that the EASI can be learned quickly and utilized reliably in the assessment of severity and extent of AD. There was consistency among the evaluators between consecutive days of evaluation. These results support the use of the EASI in clinical trials of therapeutic agents for AD.

Integrity signals

Registry

Crossref · 10.1034/j.1600-0625.2001.100102.x

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diagnostic features of atopic dermatitis
Hanifin, J. M., & Rajka, G. (1980) · Acta Dermato-Venereologica · doi:10.2340/00015555924447 · Cited by 5,086
Self-citation
The Design and Analysis of Clinical Experiments
Fleiss, J. L. (1999) · Wiley eBooks · doi:10.1002/9781118032923 · Cited by 4,819
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,304
Large sample standard errors of kappa and weighted kappa.
Fleiss, J. L., Cohen, J., & Everitt, B. S. (1969) · Psychological Bulletin · doi:10.1037/h0028106 · Cited by 1,536
Grading of the severity of atopic dermatitis.
Rajka, G., & Langeland, T. (1989) · PubMed · doi:10.2340/000155551441314 · Cited by 415
Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis
Sowden, J. M., Allen, B. R., Berth‐Jones, J., GRAHAM-BROWN, R. A. C., Motley, R., Finlay, A. Y., Salek, S., Marks, R., Ross, J., & Camp, R. D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90134-b · Cited by 411
Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children
Kang, S., Lucky, A. W., Pariser, D. M., Lawrence, I., & Hanifin, J. M. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.109812 · Cited by 329
Self-citation
A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients
Paller, A. S., Eichenfield, L. F., Leung, D. Y. M., Stewart, D., & Appell, M. L. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.109813 · Cited by 323
Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy
Hanifin, J. M., LING, M. R., Langley, R. G. B., Breneman, D., & Rafal, E. S. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.109810 · Cited by 285
Self-citation

Show all 17 references

Research works printed but not linked: 1

Fleiss J L, 1986, New York., 1

Sorted by citations

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M. H., Bieber, T. R. M., Rocklin, R. E., Ming, J. E., Ren, H., Kao, R., Simpson, E. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,435
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Chamlin, S. L., Feldman, S. R., Hanifin, J. M., Simpson, E. L., Berger, T. G., Bergman, J. N., Cohen, D. E., Cooper, K. D., et al. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.10.010 · Cited by 1,305
Self-citation
Epidemiology of atopic dermatitis in adults: Results from an international survey
Barbarot, S., Auzière, S., Gadkari, A., Girolomoni, G., Puig, L., Simpson, E. L., Margolis, D. J., de Bruin-Weller, M. S., & Eckert, L. (2018) · Allergy · doi:10.1111/all.13401 · Cited by 890
Targeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
Tight junction defects in patients with atopic dermatitis
Benedetto, A. D., Rafaels, N. M., McGirt, L. Y., Ivanov, A. I., Georas, S. N., Cheadle, C., Berger, A. E., Zhang, K., Vidyasagar, S., Yoshida, T., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.10.018 · Cited by 750
Self-citation
The Patient-Oriented Eczema Measure
Charman, C. R., Venn, A. J., & Williams, H. C. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.12.1513 · Cited by 660
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
Self-citation
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
Thaçi, D., Simpson, E. L., Beck, L. A., Bieber, T. R. M., Blauvelt, A., Papp, K. A., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H. L., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 573
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Simpson, E. L., Sinclair, R., Forman, S., Wollenberg, A., Aschoff, R., Cork, M., Bieber, T., Thyssen, J. P., Yosipovitch, G., Flohr, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30732-7 · Cited by 522
Toward a new generation of smart skins
Someya, T., & Amagai, M. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0079-1 · Cited by 499
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Bieber, T. R. M., Simpson, E. L., Silverberg, J. I., Thaçi, D., Paul, C. F., Pink, A., Kataoka, Y., Chu, C., DiBonaventura, M., Rojo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2019380 · Cited by 481
Treatment of Staphylococcus aureus Colonization in Atopic Dermatitis Decreases Disease Severity
Huang, J. T., Abrams, M., Tlougan, B. E., RADEMAKER, A. W., & Paller, A. S. (2009) · PEDIATRICS · doi:10.1542/peds.2008-2217 · Cited by 479
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
Hamilton, J. D., Suárez‐Fariñas, M., Dhingra, N., Cardinale, I. R., Li, X., Kostić, A., Ming, J. E., Radin, A. R., Krueger, J. G., Graham, N. M. H., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.013 · Cited by 472
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Silverberg, J. I., Simpson, E. L., Thyssen, J. P., Gooderham, M., Chan, G. L., Feeney, C., Biswas, P., Valdez, H., DiBonaventura, M., Nduaka, C. I., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.1406 · Cited by 413
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
Yosipovitch, G., Reaney, M. D., Mastey, V., Eckert, L., Abbé, A., Nelson, L. M., Clark, M., Williams, N., Chen, Z., Ardeleanu, M., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17744 · Cited by 405
Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children
Wahn, U., Bos, J. D., Goodfield, M. J. D., Caputo, R., Papp, K. A., Manjra, A. I., DOBOZY, A., Paul, C. F., Molloy, S., Hultsch, T., et al. (2002) · PEDIATRICS · doi:10.1542/peds.110.1.e2 · Cited by 402
Self-citation
Effects of early-life exposure to allergens and bacteria on recurrent wheeze and atopy in urban children
Lynch, S. V., Wood, R. A., Boushey, H. A., Bacharier, L. B., Bloomberg, G. R., Kattan, M., O’Connor, G. T., Sandel, M. T., Calatroni, A., Matsui, E. C., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.04.018 · Cited by 404
Barrier Function and Water-Holding and Transport Properties of Infant Stratum Corneum Are Different from Adult and Continue to Develop through the First Year of Life
Nikolovski, J., Stamatas, G. N., Kollias, N., & Wiegand, B. C. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701239 · Cited by 388
What are the best outcome measurements for atopic eczema? A systematic review
Schmitt, J., Langan, S., & Williams, H. C. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.08.011 · Cited by 388
Guidelines of care for atopic dermatitis
Hanifin, J. M., Cooper, K. D., Ho, V. C., Kang, S., Krafchik, B. R., Margolis, D. J., Schachner, L. A., Sidbury, R., Whitmore, S. E., Sieck, C. K., et al. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.08.003 · Cited by 392
Self-citation
Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents
Eichenfield, L. F., Lucky, A. W., Boguniewiczc, M., Langley, R. G. B., Cherille, R., Marshalle, K., Bushe, C., & Graeber, M. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.122187 · Cited by 364
Self-citation
Atopic Dermatitis: Natural History, Diagnosis, and Treatment
Thomsen, S. F. (2014) · ISRN Allergy · doi:10.1155/2014/354250 · Cited by 356
Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?
Mollanazar, N. K., Smith, P. K., & Yosipovitch, G. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8488-5 · Cited by 354
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial
Guttman-Yassky, E., Blauvelt, A., Eichenfield, L. F., Paller, A. S., Armstrong, A. W., Drew, J., Gopalan, R., & Simpson, E. L. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.0079 · Cited by 341
Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection
Fishbein, A. B., Silverberg, J. I., Wilson, E. J., & Ong, P. Y. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.06.044 · Cited by 336
Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial
Nakatsuji, T., Hata, T. R., Tong, Y., Cheng, J. Y., Shafiq, F., Butcher, A. M., Salem, S. S., Brinton, S. L., Rudman Spergel, A. K., Johnson, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01256-2 · Cited by 333
The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials
Schmitt, J., Spuls, P. I., Thomas, K. S., Simpson, E., Furue, M., Deckert, S., Dohil, M., Apfelbacher, C., Singh, J. A., Chalmers, J., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.07.043 · Cited by 319
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
Guttman‐Yassky, E., Silverberg, J. I., Nemoto, O., Forman, S. B., Wilke, A. V., Prescilla, R. P., de la Peña, A., Nunes, F. P., Janes, J., Gamalo, M., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.018 · Cited by 319
Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape
Boguniewicz, M., Fonacier, L. S., Guttman‐Yassky, E., Ong, P. Y., Silverberg, J. I., & Farrar, J. R. (2017) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2017.10.039 · Cited by 308
Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial
Gong, J. Q., Lin, L., Lin, T., Hao, F., Zeng, F. Q., Bi, Z., Yi, D., & Zhao, B. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07410.x · Cited by 307
Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults
Simpson, E. L., Bieber, T. R. M., Eckert, L., Wu, R., Ardeleanu, M., Graham, N. M. H., Pirozzi, G., & Mastey, V. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.10.043 · Cited by 306
Severity strata for Eczema Area and Severity Index ( EASI ), modified EASI , Scoring Atopic Dermatitis ( SCORAD ), objective SCORAD , Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis
Chopra, R., Vakharia, P. P., Sacotte, R. M., Patel, N., Immaneni, S., White, T., Kantor, R. W., Hsu, D. Y., & Silverberg, J. I. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15641 · Cited by 302
Assessment of clinical signs of atopic dermatitis: A systematic review and recommendation
Schmitt, J. M., Langan, S., Deckert, S., Svensson, Å., von Kobyletzki, L., Thomas, K. S., & Spuls, P. I. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.008 · Cited by 295
The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability
Held, E., Skoet, R., Johansen, J. D., & Agner, T. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.06305.x · Cited by 291
Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency
Kežić, S., O’Regan, G. M., Lutter, R., Jakaša, I., Koster, E. S., Saunders, S. P., Caspers, P. J., Kemperman, P. M. J. H., Puppels, G. J., Sandilands, A., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.12.989 · Cited by 276
Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug
Kapp, A., Papp, K. A., Bingham, A., Fölster‐Holst, R., Ortonne, J. P., Potter, P. C., Gulliver, W. P. F., Paul, C. F., Molloy, S., Barbier, N., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.126500 · Cited by 270
Self-citation
Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment
Wollenberg, A., Reitamo, S., Atzori, F., Lahfa, M., Ruzicka, T., Healy, E., Giannetti, A., Bieber, T. R. M., Vyas, J., Deleuran, M. S., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2008.01683.x · Cited by 266
Guidelines for management of atopic dermatitis
Saeki, H., Furue, M., Furukawa, F., Hide, M., Ohtsuki, M., Katayama, I., 佐々木, り., Suto, H., & Takehara, K. (2009) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2009.00706.x · Cited by 266
Emollients and moisturisers for eczema
van Zuuren, E. J., Fedorowicz, Z., Christensen, R., Lavrijsen, A. P. M., & Arents, B. W. M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012119.pub2 · Cited by 278
Phenotype of atopic dermatitis subjects with a history of eczema herpeticum
Beck, L. A., Boguniewicz, M., Hata, T. R., Schneider, L. C., Hanifin, J. M., Gallo, R. L., Paller, A. S., Lieff, S., Reese, J., Zaccaro, D. J., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.05.020 · Cited by 262
Self-citation
Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe: PO-SCORAD self-assessment scale validation
Stalder, J.-F., Barbarot, S., Wollenberg, A., Holm, E. A., De Raeve, L., Seidenari, S., Oranje, A., Deleuran, M., Cambazard, F., Svensson, A., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2011.02577.x · Cited by 255
Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis
Reitamo, S., Rustin, M. H. A., Ruzicka, T., Cambazard, F., Kalimo, K., Friedmann, P. S., Schoepf, E., Lahfa, M., Diepgen, T. L., Judodihardjo, H., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121832 · Cited by 254
Anti-CD20 (rituximab) treatment improves atopic eczema
Simon, D., Radonjic‐Hoesli, S., Kostylina, G., Yawalkar, N., & Simon, H. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.11.016 · Cited by 253
Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Kaino, H., & Nagata, T. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.015 · Cited by 242
Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum
Gao, P.-S., Rafaels, N. M., Hand, T. A., Murray, T., Boguniewicz, M., Hata, T. R., Schneider, L. C., Hanifin, J. M., Gallo, R. L., Gao, L., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.07.034 · Cited by 242
Self-citation
Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis
Reitamo, S., van Leent, E. J. M., Ho, V., Harper, J. I., Ruzicka, T., Kalimo, K., Cambazard, F., Rustin, M. H. A., Taı̈eb, A., Gratton, D., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121831 · Cited by 236
The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy
Hedin, C. R. H., Vavricka, S., Stagg, A. J., Schoepfer, A. M., Raine, T., Puig, L., Pleyer, U., Navarini, A. A., Jong, A. E. V. D. M., Maul, J., et al. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy191 · Cited by 232
Burden of skin pain in atopic dermatitis
Vakharia, P. P., Chopra, R., Sacotte, R. M., Patel, K. R., Singam, V., Patel, N., Immaneni, S., White, T., Kantor, R. W., Hsu, D. Y., et al. (2017) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2017.09.076 · Cited by 222
GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis
Guttman-Yassky, E., Pavel, A. B., Zhou, L., Estrada, Y. D., Zhang, N., Xu, H., Peng, X., Wen, H.-C., Govas, P., Gudi, G., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.053 · Cited by 220
Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Adults: A Six-Month Study
Meurer, M., Fölster‐Holst, R., Wozel, G., Weidinger, G., Jünger, M., Bräutigam, M., & f for the CASM-DE-01 Study Group (2002) · Dermatology · doi:10.1159/000065863 · Cited by 219
The Eczema Area and Severity Index – a practical guide
Hanifin, J. M., Baghoomian, W., Grinich, E., Leshem, Y. A., Jacobson, M., & Simpson, E. L. (2022) · Dermatitis · doi:10.1097/der.0000000000000895 · Cited by 213
Self-citation
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort
Faiz, S., Giovannelli, J., Podevin, C., Jachiet, M., Bouaziz, J.-D., Reguiai, Z., Nosbaum, A., Lasek, A., Ferrier le Bouedec, M.-C., Du Thanh, A., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.053 · Cited by 210
Japanese guidelines for atopic dermatitis 2020
Katoh, N., Ohya, Y., Ikeda, M., Ebihara, T., Katayama, I., Saeki, H., Shimojo, N., Tanaka, A., Nakahara, T., Nagao, M., et al. (2020) · Allergology International · doi:10.1016/j.alit.2020.02.006 · Cited by 205
Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants
Ho, V. C., Gupta, A. K., Kaufmann, R., Todd, G., Vanaclocha, F., Takaoka, R., Fölster‐Holst, R., Potter, P., Marshall, K., Thurston, M., et al. (2003) · The Journal of Pediatrics · doi:10.1067/mpd.2003.65 · Cited by 199
Self-citation
Topical tacrolimus for atopic dermatitis
Cury‐Martins, J., Martins, C. R., Aoki, V., de Góis, A. F. T., Ishii, H. A., & da Silva, E. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009864.pub2 · Cited by 205
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
Guttman‐Yassky, E., Simpson, E. L., Reich, K., Kabashima, K., Igawa, K., Suzuki, T., Mano, H., Matsui, T., Esfandiari, E., & Furue, M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02037-2 · Cited by 190
Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine
Bieber, T. (2012) · Allergy · doi:10.1111/all.12049 · Cited by 188
Atopic Dermatitis and Fungi
Faergemann, J. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.4.545-563.2002 · Cited by 187
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis
Simpson, E. L., Bissonnette, R., Eichenfield, L. F., Guttman‐Yassky, E., King, B., Silverberg, J. I., Beck, L. A., Bieber, T. R. M., Reich, K., Kabashima, K., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.104 · Cited by 185
Distinct patterns of brain activity evoked by histamine-induced itch reveal an association with itch intensity and disease severity in atopic dermatitis
Ishiuji, Y., Coghill, R. C., Patel, T. S., Oshiro, Y., Kraft, R., & Yosipovitch, G. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09308.x · Cited by 180
Disease severity, scratching, and sleep quality in patients with atopic dermatitis
Bender, B. G., Ballard, R., Canono, B. P., Murphy, J. R., & Leung, D. Y. M. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.10.010 · Cited by 176
Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children
Camargo, C. A., Ganmaa, D., Sidbury, R., Erdenedelger, K., Radnaakhand, N., & Byamba, K. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.08.002 · Cited by 175
Association between obesity and atopic dermatitis in childhood: A case-control study
Silverberg, J. I., Kleiman, E., Lev‐Tov, H. A., Silverberg, N. B., Durkin, H. G., Joks, R. O., & Smith-Norowitz, T. A. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.01.063 · Cited by 171
Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016
Saeki, H., Nakahara, T., Tanaka, A., Kabashima, K., Sugaya, M., Murota, H., Ebihara, T., Kataoka, Y., Aihara, M., Etoh, T., et al. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13392 · Cited by 171
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis
Eichenfield, L. F., Flohr, C., Sidbury, R., Siegfried, E. C., Szalai, Z. Z., Galus, R., Yao, Z., Takahashi, H., Barbarot, S., Feeney, C., et al. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.2830 · Cited by 170
Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010
Rehal, B., & Armstrong, A. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017520 · Cited by 168
A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis
Peppers, J., Paller, A. S., Maeda-Chubachi, T., Wu, S., Robbins, K., Gallagher, K., & Kraus, J. E. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.047 · Cited by 165
IFN-gamma-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis
Horikawa, T. (2002) · International Immunology · doi:10.1093/intimm/dxf044 · Cited by 165
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
Blauvelt, A., Silverberg, J. I., Lynde, C. W., Bieber, T. R. M., Eisman, S., Zdybski, J., Gubelin, W., Simpson, E. L., Valenzuela, F., Criado, P. R., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.05.075 · Cited by 164
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)
Simpson, E. L., Gadkari, A. S., Worm, M., Soong, W., Blauvelt, A., Eckert, L., Wu, R., Ardeleanu, M., Graham, N. M. H., Pirozzi, G., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.04.054 · Cited by 164
Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)
Chalmers, J. R., Thomas, K. S., Apfelbacher, C., Williams, H. C., Prinsen, C. A. C., Spuls, P. I., Simpson, E., Gerbens, L. A. A., Boers, M., Barbarot, S., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16543 · Cited by 160
Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study
Peserico, A., Städtler, G., Sebastian, M., Suárez‐Fernández, R., Vick, K., & Bieber, T. R. M. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08436.x · Cited by 159
Measuring Atopic Dermatitis Severity in Randomized Controlled Clinical Trials: What Exactly Are We Measuring?
Charman, C. R., Chambers, C., & Williams, H. C. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12251.x · Cited by 159
Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme
Barbier, N., Paul, C. F., Luger, T. A., Allen, R., Prost, Y. D., Papp, K. A., Eichenfield, L. F., Cherill, R., & Hanifin, J. M. (2004) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.05696.x · Cited by 154
Self-citation
CCL18 Is Expressed in Atopic Dermatitis and Mediates Skin Homing of Human Memory T Cells
Günther, C., Bello-Fernández, C., Kopp, T., Kund, J., Carballido‐Perrig, N., Hinteregger, S., Fassl, S., Schwärzler, C., Lametschwandtner, G., Stingl, G., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1723 · Cited by 153
The Objective Severity Assessment of Atopic Dermatitis Score
Sugarman, J. L., Fluhr, J. W., Fowler, A. J., Bruckner, T., Diepgen, T. L., & Williams, M. L. K. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.11.1417 · Cited by 152
Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studies
Paller, A. S., Lebwohl, M., Fleischer, A. B., Antaya, R. J., Langley, R. G. B., Kirsner, R. S., Blum, R. R., Rico, M. J., Jaracz, E., Crowe, A. W., et al. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.12.038 · Cited by 151
What causes itch in atopic dermatitis?
Yosipovitch, G., & Papoiu, A. D. P. (2008) · Current Allergy and Asthma Reports · doi:10.1007/s11882-008-0049-z · Cited by 150
Clinical Trial of Human Umbilical Cord Blood-Derived Stem Cells for the Treatment of Moderate-to-Severe Atopic Dermatitis: Phase I/IIa Studies
Kim, H., Lee, J. H., Roh, K.-H., Jun, H. J., Kang, K., & Kim, T. (2016) · Stem Cells · doi:10.1002/stem.2401 · Cited by 150
Reliability of Clinician Erythema Assessment grading scale
Tan, J. K. L., Liu, H., Leyden, J. J., & Leoni, M. J. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.05.044 · Cited by 149
Increased serum levels of interleukin 33 in patients with atopic dermatitis
Tamagawa‐Mineoka, R., Okuzawa, Y., Masuda, K., & Katoh, N. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.01.867 · Cited by 149
Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis
Paller, A. S., Flohr, C., Cork, M. J., Bewley, A., Blauvelt, A., Hong, H., Imafuku, S., Schuttelaar, M. L. A., Simpson, E. L., Soong, W., et al. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.0627 · Cited by 148
Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study
Nakagawa, H., Nemoto, O., Igarashi, A., & Nagata, T. (2017) · British Journal of Dermatology · doi:10.1111/bjd.16014 · Cited by 145
First experience of topical SDZ ASM 981 in children with atopic dermatitis
Harper, J. I., Green, A., Scott, G., Gruendl, E., Dorobek, B., Cardno, M., & Burtin, P. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04133.x · Cited by 144
Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection
Navarini, A. A., French, L. E., & Hofbauer, G. F. L. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.09.009 · Cited by 140
Therapeutic responses to Roseomonas mucosa in atopic dermatitis may involve lipid-mediated TNF-related epithelial repair
Myles, I. A., Castillo, C. R., Barbian, K. D., Kanakabandi, K., Virtaneva, K., Fitzmeyer, E., Paneru, M., Otaizo-Carrasquero, F., Myers, T. G., Markowitz, T. E., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz8631 · Cited by 139
Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis
Werfel, T., Layton, G. R., Yeadon, M., Whitlock, L. A., Osterloh, I. H., Jimenez, P. A., Liu, W. M., Lynch, V., Asher, A., Tsianakas, A., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.07.047 · Cited by 138
Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis
Silverberg, J. I., Thyssen, J. P., Fahrbach, K. R., Mickle, K., Cappelleri, J. C., Romero, W., Cameron, M. C., Myers, D. E., Clibborn, C., & DiBonaventura, M. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17351 · Cited by 139
Percutaneous penetration of sodium lauryl sulphate is increased in uninvolved skin of patients with atopic dermatitis compared with control subjects
Jakaša, I., de Jongh, C. M., Verberk, M. M., Bos, J. D., & Kežić, S. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07319.x · Cited by 137
Colonization With Staphylococcus aureus in Atopic Dermatitis Patients: Attempts to Reveal the Unknown
Ogonowska, P., Gilaberte, Y., Barańska‐Rybak, W., & Nakonieczna, J. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.567090 · Cited by 142
Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis
Hanifin, J. M., Paller, A. S., Eichenfield, L. F., Clark, R. A. F., Korman, N. J., Weinstein, G. D., Caro, I., Jaracz, E., & Rico, M. J. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.04.062 · Cited by 136
Self-citation
Skin care education and individual counselling versus treatment as usual in healthcare workers with hand eczema: randomised clinical trial
Ibler, K. S., Jemec, G. B. E., Diepgen, T. L., Gluud, C. N., Hansen, J. L., Winkel, P., Thomsen, S. F., & Agner, T. (2012) · BMJ · doi:10.1136/bmj.e7822 · Cited by 135
Phase 2a, randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study of a H4R‐antagonist ( JNJ ‐39758979) in J apanese adults with moderate atopic dermatitis
Murata, Y., Song, M., Kikuchi, H., Hisamichi, K., Xu, X. L., Greenspan, A. J., Kato, M., Chiou, C., Kato, T., Guzzo, C. A., et al. (2014) · The Journal of Dermatology · doi:10.1111/1346-8138.12726 · Cited by 133
Profile of skin barrier proteins (filaggrin, claudins 1 and 4) and Th1/Th2/Th17 cytokines in adults with atopic dermatitis
Batista, D. I. S., Perez, L., Orfali, R. L., Zaniboni, M. C., Samorano, L. P., Pereira, N. V., Sotto, M. N., Ishizaki, A. S., Oliveira, L. M. D. S., Sato, M. N., et al. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12753 · Cited by 132
Clinical practice guidelines for the management of atopic dermatitis 2018
Katoh, N., Ohya, Y., Ikeda, M., Ebihara, T., Katayama, I., Saeki, H., Shimojo, N., Tanaka, A., Nakahara, T., Nagao, M., et al. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.15090 · Cited by 131
The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey
Whiteley, J., Emir, B., Seitzman, R., & Makinson, G. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1195733 · Cited by 130
A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis
Reitamo, S., Ortonne, J. ‐., Sand, C., Cambazard, F., Bieber, T. R. M., Fölster‐Holst, R., Vena, G., Bos, J. D., Fabbri, P., Larsen, C. G., et al. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06592.x · Cited by 130
Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics
Mansouri, Y., & Guttman‐Yassky, E. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4050858 · Cited by 129
0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial
Reitamo, S., Harper, J. I., Bos, J. D., Cambazard, F., Bruijnzeel-Koomen, C. A. F. M., van der Valk, P. G. M., Smith, C. H., Moss, C., DOBOZY, A., Palatsi, R., et al. (2004) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2004.05782.x · Cited by 128

Authors: Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E.
Affiliations: Oregon Health & Science University (US)
Novartis (Switzerland) (CH)
Shiga University of Medical Science (JP)
Corresponding author: Hanifin, J. M.
ORCID: Hanifin, J. M.
Venue: Experimental Dermatology
Publisher: Wiley
Published: 2001-02
Volume: 10
Issue: 1
Pages: 11-18
ISSN: 0906-6705 (ISSN-L)
1600-0625
DOI: 10.1034/j.1600-0625.2001.100102.x
OpenAlex: W2117359358
Cited by: 1,200
References: 17
Citations by year: 2026: 69 · 2025: 85 · 2024: 92 · 2023: 101 · 2022: 84 · 2021: 98 · 2020: 82 · 2019: 63 · 2018: 47 · 2017: 46 · 2016: 53 · 2015: 28 · 2014: 43 · 2013: 23 · 2012: 21
FWCI: 20.78
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2713 d)
Locations: Experimental Dermatology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Reliability and Agreement in Measurement
Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
Keywords: Eczema Area and Severity Index, atopic dermatitis, inter-rater reliability, intra-rater reliability, disease severity assessment, disease extent assessment, clinical trial outcome measures
MeSH terms: Adolescent, Adult, Child, Child, Preschool, Dermatitis, Atopic, Dermatology, Eczema, Humans, Infant, Infant, Newborn, Severity of Illness Index, Reproducibility of Results, Cohort Studies, Observer Variation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks